The majority of literature reports concerning nanoparticle-based anticancer drug delivery systems show that the nanoparticle formulation often results in significant enhancement of anticancer activity in vitro (based on conventional cell viability assays) even in the absence of active targeting ligands. However, our group often obtains similar IC50 values for the free drug and nanoparticle formulation (e.g. using PEG-PCL, PEG-PLA, and PLGA NPs) after 24-72 h incubation with the cells. Any thoughts?
Has the encapsulation been WELL confirmed, established through different analyses? Is the encapsulation efficiency high enough to encapsulate the bioactive agent to produce desired enhancements in bioactivity AND is it free from any surface attachments and ANY amount of active agents present in the final, being tested, nanoformulation? How these steps were made sure? Any look back in these aspects?!
Dear Suhair,
Indeed, PLGA copolymers are excellent delivery carriers for controlled administration of drugs, peptides, proteins…The release behavior is depending on the nature of PLGA matrix, of API (active pharmaceutical ingredients/drugs) and their loading, hydrophilicity, volume to surface ratio, quality of encapsulation, presence or not of specific additives, etc.
Please consider that some PLGA delivering systems are frequently indicated for the long-term drug release (1 to 6 months). Release speed can be controlled by their molecular weight & copolymer ratio, i.e., PLGA copolymer Ld/Gd 50:50 has the fastest degradation rate by hydrolysis (~ one month).
Ideally, the drug delivering profile must be adapted to the requirements of your application.
Lastly, I believe that in explanation of results it will be necessary understand and then, to design your drug delivering system by considering the main constraints, but is not very easy!
Good luck in your R&D study and best regards,
Marius
Suhair Sunoqrot Enhanced anticancer activity not only depends on the drug particles reached at the specific site, It also depends on the intrinsic property of nanocarrier. Some nanocarriers are made up of materials having anticancer activity like hyaluronic acid. Apart from that it also depends on the type of drug and affinity of drugs towards the carcinogen cell. Some nanocarriers posses specific binder molecule on their surface which gives more anticancer activity. So read the reason in the articles why and on what basis they are reporting the enhanced anticancer activity.
Thanks and good luck
- Badges
- Science topic
- Similar topics
- Chemistry
- Nanotechnology
- Nanostructured Materials
- Nanoparticles